China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process